Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | MPO | P05164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3768853 | 0.98 | KDM4E (0.45) | KDM4EHSD17B10ALDH1A1GAAATM | |
| SCHEMBL13059432 | 0.85 | KDM4E (0.47) | KDM4EHSD17B10ALDH1A1GAAATM | |
| SCHEMBL3881237 | 0.83 | ALDH1A1 (0.47) | KDM4EHSD17B10ALDH1A1GAAATM | |
| SCHEMBL6628180 | 0.83 | LMNA (0.61) | KDM4EHSD17B10ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL6628522 | 0.81 | POLB (0.50) | KDM4EALDH1A1LMNAMPOSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3879797 | 0.81 | LMNA (0.59) | KDM4EALDH1A1LMNASMN1; SMN2KMT2A | |
| SCHEMBL25820060 | 0.81 | GAA (0.45) | KDM4EHSD17B10ALDH1A1GAAATM | |
| Hydrochloric Acid SCHEMBL3770405 | 0.80 | POLB (0.49) | KDM4EALDH1A1LMNAMPOSMN1; SMN2 | |
| SCHEMBL994597 | 0.79 | CYP1A2 (0.60) | KDM4EALDH1A1SMN1; SMN2KMT2AHTT | |
| SCHEMBL6627791 | 0.78 | KDM4E (0.56) | KDM4EHSD17B10ALDH1A1ATMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311741-A1 | Bicyclosulfonyl Acid (BCSA) Compounds and Their Use as Therapeutic Agents | INHIBOX LTD. (GB) | 2010-12-09 | — | — | US | disclosed |
| US-20100311741-A1 | Bicyclosulfonyl Acid (BCSA) Compounds and Their Use as Therapeutic Agents | INHIBOX LTD. (GB) | 2010-12-09 | — | — | US | disclosed |
| WO-2008142376-A1 | BICYCLOSULFONYL ACID (BCSA) COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | INHIBOX LTD. (GB) | 2008-11-27 | — | — | WO | disclosed |
| EP-1027332-B1 | NOVEL LACTAM METALLOPROTEASE INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-05-26 | — | — | EP | disclosed |
| US-6610731-B2 | Antiinflammatory | BRISTOL-MYERS SQUIBB COMPANY | 2003-08-26 | — | — | US | disclosed |
| US-20030134827-A1 | Novel lactam metalloprotease inhibitors | DUAN JINGWU (US) | 2003-07-17 | — | — | US | disclosed |
| US-6403632-B1 | CYCLIC AMIDE DERIVATIVE | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2002-06-11 | — | — | US | disclosed |
| EP-1027332-A1 | NOVEL LACTAM METALLOPROTEASE INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2000-08-16 | — | — | EP | disclosed |
| US-6057336-A | ANTIINFLAMMATORY AGENTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2000-05-02 | — | — | US | disclosed |
| WO-1999018074-A1 | NOVEL LACTAM METALLOPROTEASE INHIBITORS | Britol-Myers Squibb Pharma Company (US) | 1999-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311741-A1 | Bicyclosulfonyl Acid (BCSA) Compounds and Their Use as Therapeutic Agents | TNF, CS, COASY | KDM4E 3812/4885HSD17B10 835/4885ALDH1A1 1941/4885 |
| US-20030134827-A1 | Novel lactam metalloprotease inhibitors | ADAM9, ADAM8, ADAM17 | KDM4E 1715/4885HSD17B10 714/4885ALDH1A1 1466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.